<DOC>
	<DOC>NCT02346877</DOC>
	<brief_summary>This study will evaluate whether the effect of personalized patient counselling tool, Information-Motivation-Strategy (IMS) based on the results of the Beliefs about Medicines Questionnaire (BMQ) will improve persistence of Enbrel (etanercept) therapy at week 52 in subjects with rheumatoid arthritis over the historical control as estimated by the standard of care.</brief_summary>
	<brief_title>Evaluate Effects of Personalized Patient Counselling for Enbrel速 Therapy in Adults With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Subject has provided informed consent prior to any study specific procedures diagnosed with rheumatoid arthritis and eligible for treatment with Enbrel速 (etanercept) Subject has been prescribed and has access to commercial Enbrel速 (etanercept) (50mg once weekly) according to the subject's health insurance Completion of all required safety assessments before starting treatment with Enbrel速 (etanercept) Other Inclusion Criteria May apply. previously received treatment with a biologic disease modifying antirheumatic drug (DMARD) and/or Tofacitinib. Malignancy (except nonmelanoma skin cancers, cervical or breast ductal carcinoma in situ) within the last 5 years refusal to consent to enroll in the Enliven program Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s) Other Exclusion Criteria May Apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Enbrel</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>